Browse > Article

CONSISTENCY AND ASYMPTOTIC NORMALITY OF A MODIFIED LIKELIHOOD APPROACH CONTINUAL REASSESSMENT METHOD  

Kang, Seung-Ho (Department of Statistics, Ewha Womans University)
Publication Information
Journal of the Korean Statistical Society / v.32, no.1, 2003 , pp. 33-46 More about this Journal
Abstract
The continual reassessment method (CRM) provides a Bayesian estimation of the maximum tolerated dose (MTD) in phase I clinical trials. The CRM has been proposed as an alternative design of the standard design. The CRM has been modified to improve practical feasibility and, recently, the likelihood approach CRM has been proposed. In this paper we investigate the consistency and asymptotic normality of the modified likelihood approach CRM in which the maximum likelihood estimate is used instead of the posterior mean. Small-sample properties of the consistency is examined using complete enumeration. Both the asymptotic results and their small-sample properties show that the modified CRML outperforms the standard design.
Keywords
Sequential design; clinical trial; maximum likelihood estimate; oncology;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Investigation on the modified continual reassessment method in phase I clinical trial /
[ Kang, S. H. ] / The Korean Journal of Applied Statistics   과학기술학회마을
2 Methods for dose finding studies in cancer trials: A review and results of a Monte Carlo study /
[ O'Quigley, J.;Chevret, S. ] / Statistics in Medicine   ScienceOn
3 An evaluation of phase I cancer clinical trial designs /
[ Ahn, C. ] / Statistics in Medicine   ScienceOn
4 Continual reassessment method: A likelihood approach /
[ O'Quigley, J;Shen, L. ] / Biometrics   ScienceOn
5 Continual reassessment method: A practical design for phase I clinical trials in cancer /
[ O'Quigley, J.;Pepe, M.;Fisher, M. ] / Biometrics   ScienceOn
6 An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate an greater range of doses /
[ Moller, S. ] / Statistics in Medicine   ScienceOn
7 Practical modificatios of the continual reassessment method for phase I cancer clinical trials /
[ Faries, D. ] / Journal of Biopharmaceutical Statistics   ScienceOn
8 The expected toxicity rate at the maximum tolerated dose in the standard phase I cancer clinical trial design /
[ Kang, S. H.;Ahn, C. ] / Drug Information Journal   ScienceOn
9 Some practical improvements in the continual reassessment method for phase I studies /
[ Goodman, S.;Zahurak, M.;Piantadosi, S. ] / Statistics in Medicine   ScienceOn